Bevacizumab Bevatas 100mg - Anticancer drugs | Intas | MHP
BEVATAS RENAL CELL CARCINOMA DESCRIPTION Bevacizumab is a drug sold under the name of Bevatas 400mg and which is categorized as monoclonal anti-body & anti-angiogenesis When Bevatas concomitant use with human monoclonal antibody IgG1, that circumstance and prohibits the biological action of human vascular endothelial growth factor (VEGF) USAGE Bevatas 400mg is indicated for the treatment of some of the conditions like Metastatic colon or rectal cancer Non-squamous, non-small cell lung cancer Glioblastoma Metastatic renal cell cancer Metastatic cervical cancer Epithelial ovarian, fallopian tube or peritoneal cancer MECHANISM OF ACTION Bevatas 400mg Injection comprises an active compound like Bevacizumab which binds to VEGF and avoid the communication of VEGF to its receptors like Flt-1 & KDR) present on the surface of the cells This interaction prevents endothelial cell multiplication and new blood vessel production occurs Hence in counts cessation ...